---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-025418"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2024-05-28T23:59:59+00:00"
generated_at: "2026-06-01T07:57:19.951444+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Esperion shareholders approve 6.25M share increase to 2022 stock plan and 6.175M increase to ESPP

## Summary
- Stockholders re-elected directors Antonio M. Gotto Jr. and Nicole Vitullo with 87.9M and 91.0M votes for, respectively.
- Advisory say-on-pay proposal approved with 70.7M votes (74% of votes cast).
- Ratification of Ernst & Young as auditor for FY2024 approved with 136.8M votes (98.3% of votes cast).
- Amendment to 2022 Stock Option Plan increasing authorized shares by 6,250,000 approved with 88.1M votes.
- Amendment to 2020 ESPP increasing reserved shares by 6,175,000 approved with 88.8M votes.

## SEC filing metadata
- accession: 0001628280-24-025418
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2024-05-28T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828024025418/0001628280-24-025418-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828024025418/espr-20240523.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-025418
- JSON: https://secwatch.observer/filing/0001628280-24-025418.json
- Plain text: https://secwatch.observer/filing/0001628280-24-025418.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.